At NervGen, we take your privacy very seriously and are committed to safeguarding your personal data that may enter into our possession when you visit our website. This Privacy Policy describes what information we collect, store, use, disclose or otherwise process about you and for what purposes, how we use that information, and the steps we have taken to protect that information.
The type of information we collect about you depends on your interactions with us.
When you visit our website, including our social media sites, we may collect information about you including, but not limited to:
Personal information, such as your name, address and email address;
Professional information, such as your job title or occupation, educational information, employer names, professional qualifications, references, and affiliations; and
Correspondence, such as information you provide when you request information for investors, apply for a job posting, or otherwise correspond with us.
As you navigate our website, including when using a mobile device, we (and our service provider) may collect information from your computer or other device, such as your device identifier, Internet Protocol (IP) address, your browser related information, pages you viewed, your search queries, information about the date and time of your requests, and other information provided by tracking technologies. Please refer to Your Privacy Choices below for more details.
We use your information in connection with the services we provide through our website, including responding to your inquiries or requests, providing and improving the content on our site, communicating information regarding our relationship to you or regarding our services.
We will disclose personal information to third parties only in accordance with applicable laws, and appropriate safeguards will be established, where applicable, to protect your information.
We may share information with third parties to help us perform the functionalities and services on our website, protect us from cyberattacks, and comply with auditors to ensure our internal processes function as intended.
We will also disclose information if we have reason to believe it is necessary or appropriate to comply with applicable laws or regulations; in response to a court order, subpoena, search warrant, or other legal or regulatory requests or processes; to enforce our terms and conditions; and to protect our rights, property, privacy, and safety and that of yours and others.
We may transfer your personal information, as permitted by applicable law, in connection with a merger, consolidation, sale, acquisition, divestiture, restructuring, reorganization, dissolution, bankruptcy or other change of ownership or control of NervGen, including any of our affiliates.
You have a choice in the information you share with us. If we provide you with any mailings or other communication, you can always opt out of that communication.
We may collect information about you and your computer using “cookies” or similar tracking technologies. A cookie is a small data file stored on your device by a website and allows the website to remember your actions, browser activities, and preferences. We use third-party cookies for the following purposes:
Optimize and personalize your user experience, for example, by remembering your preferences.
Learn how the site is used by collecting information related to our web traffic, such as the number of visitors to our site, the pages visited, and other information that would allow us to provide better content to visitors.
You can reject or manage cookies in your web browser setting. Please note, however, that if you disable cookies when visiting our site, your user experience will be affected. Some parts of our site may not be available, and some features may not work as designed.
We will protect all personal information we collect in accordance with this Privacy Policy and take reasonable steps to ensure that it is treated lawfully. We employ reasonable procedural and technological security measures in protecting your personal information. However, no website is entirely secure and we cannot guarantee the security of information transmitted online. You should protect the account information in your possession as well.
Our website may contain links to third-party websites or digital services. These are provided for your browsing convenience only and are not endorsements of the third-parties or the information presented. Our Privacy Policy does not apply to these third-party websites or services. If you choose to visit a third-party website or service, the privacy policy of that site applies.
Our website is not directed or intended for children, and we will not knowingly collect information from any individual under the age of 13, or from any individual under the age of majority in their State or Province of residence without the consent of their parent or legal guardian. Please contact us immediately at info@nervgen.com if you believe we might have collected personal information from someone under the age of 13.
We reserve the right to modify this Privacy Policy at our discretion. If we make any material changes to this Privacy Policy, we will notify you, either directly, where and when we are legally required to do so, or by posting a new privacy policy on our website. Any modifications to this Privacy Policy will be effective upon our posting on our website. Your continued use of our website after the posting of any modified Privacy Policy constitutes your acceptance of the terms of the modified Privacy Policy.
If you have any questions or concerns regarding our Privacy Policy, please send us an email at: info@nervgen.com, or write to us at:
NervGen Pharma Corp.
Corporate Head Office
112-970 Burrard Street
Unit 1290
Vancouver, BC, Canada
V6Z 2R4
Phone: (778) 731-1711
This Privacy Policy was last updated on June 13, 2022.
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |